GRAL: Jeff Bezos' stock pick

PARAGRAPH 1 --- Grail Inc. (NASDAQ: GRAL), a cancer detection company spun off from Illumina in 2024, saw its stock plummet by over 40% from its peak following mixed trial results. Despite the setback, the company remains a prominent pick of Jeff Bezos, who has a history of backing disruptive healthcare platforms. Bezos' investment in Grail occurred before the stock's significant decline.

PARAGRAPH 2 --- The biotechnology sector, particularly cancer diagnostics, is affected by Grail's performance. The company's Galleri test, which aims to detect multiple cancer types from a single blood draw, has the potential to reshape cancer screening. Grail's stock volatility and Bezos' involvement have drawn investor attention to the company, influencing the valuation of other biotech stocks in the sector.

PARAGRAPH 3 --- Upcoming catalysts to watch include the U.S. Food and Drug Administration's (FDA) decision on Galleri's premarket approval application, expected in the second half of 2025. Additionally, the adoption of Galleri by major health insurers will be crucial for the company's long-term success. Technical analysts should also monitor Grail's stock price action around the $100 level, as some bullish investors predict it could reach this price within a year.